Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2023 Earnings Guidance modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
Ligand Pharmaceuticals (NASDAQ:LGND) Earns Buy Rating from HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.76 by $0.66, Briefing.com reports. The business had revenue of $26.37 million during the quarter, compared to analysts’ expectations of $24.74 million. Ligand Pharmaceuticals […]
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $0.76 by $0.66, Briefing.com reports. Ligand Pharmaceuticals had a net margin of 11.00% and a return on equity of 3.44%. The firm had revenue of […]
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) updated its FY 2023 earnings guidance on Tuesday. The company provided EPS guidance of $4.85-$5.00 for the period, compared to the consensus EPS estimate of $4.63. The company issued revenue guidance of $124.00 million-$128.00 million, compared to the consensus revenue estimate of $131.17 million. Ligand Pharmaceuticals also updated […]